ClinicalTrials.gg
Active, not recruitingNCT05583227CROSSINGUpdated Oct 30, 2026

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

A Phase 3 interventional study of Tezepelumab and Tezepelumab in Eosinophilic Esophagitis, sponsored by AstraZeneca. Active, not recruiting at 124 sites in 22 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 30, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Enrollment
2nd of 111
368 · median 36
Started
2022
with 9 others
Phase 3
20 of 165
1 open now
Primary completion
2026-07
later than 12 of 40 live
Registered
140th of 165
by date

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 2nd largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2022, is one of 20 in phase 3, reaches primary completion later than 12 of the 40 other live ones, and was the 140th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

Read the detailed description

The study consists of a screening period of 2 to 8 weeks and a 52-week randomized double-blind placebo-controlled treatment period. After completion of the treatment period, participants will be eligible to participate in an optional active treatment extension period (lasting for 24 weeks), followed by a 12-week off-treatment safety follow-up period. Participants who will not participate in the extension period will participate in a 12-week off-treatment safety follow-up period following completion of the 52-week treatment period.

This study will randomize approximately 360 participants. The participants will be randomized at 1:1:1 ratio to the 3 treatment arms.

03

Conditions studied

  • Eosinophilic Esophagitis

Keywords

  • Chronic Esophagitis
  • Eosinophilic Esophagitis
  • Eosinophilic
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 12 to 80 years of age inclusive, at the time of signing the /assent.
  2. Weight ≥ 40 kg at Visit 1
  3. Established diagnosis of EoE with a previous EGD and esophageal confirming a diagnosis of EoE.
  4. Participants who have symptomatic EoE as defined by a history of on average at least 2 episodes of dysphagia (any severity of food going down slowly or being stuck in the throat) per week in the 4 weeks prior to Visit 1.
  5. Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the course of the study (stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups).
  6. May be on any background PPI and/or STC, during the course of the study, as long as background medications have been stable for at least 8 weeks prior to the screening/run-in period (Visit 1) and there is agreement not to change background medication or dosage unless medically indicated, during the screening/run-in and treatment period.
  7. Participants currently on leukotriene inhibitors and/or treatments for asthma or allergies that are inhaled or administered intranasally, must report a stable dose for at least 4 weeks prior to the screening/run-in period (Visit 1).
  8. If a medication for EoE (for example PPI and/or STC) is discontinued prior to the screening/run-in, there should be a of at least 8 weeks prior to Visit 1. Discontinuation of any marketed biologic (monoclonal or polyclonal antibody) should have a washout period of 4 months or 5 half-lives prior to Visit 1, whichever is longer.
  9. Participants should have previously documented standard of care treatment, which could include PPI and/or STC and/or diet.

Exclusion criteria

Exclusion Criteria:

  1. Other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, celiac disease, eosinophilic enteritis, colitis, diverticulitis, irritable bowel syndrome, or other gastrointestinal conditions as per Investigator discretion.
  2. Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation at screening.
  3. Use of a feeding tube, or having a pattern of not eating solid food >3 days of week. Solid food is defined as food that requires chewing before swallowing.
  4. Hypereosinophilic syndrome
  5. EGPA vasculitis
  6. Esophageal dilation performed within 8 weeks prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    Tezepelumab Low Dose

    Tezepelumab subcutaneous injections, in accessorised pre-filled syringes

    Biological: Tezepelumab

  • Experimental
    Tezepelumab High Dose

    Tezepelumab subcutaneous injections, in accessorised pre-filled syringes

    Biological: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo subcutaneous injections, in accessorised pre-filled syringes

    Other: Placebo

Interventions

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels

    Peak esophageal eosinophil count per HPF determined by histological analysis of 2-4 biopsies from each of the proximal, mid, and distal esophagus.

    Time frame: Week 24

  2. Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score

    The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia.

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in EoE EREFS (Endoscopic reference score )

    The EoE EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE, including esophageal edema, rings, exudates, furrows, and stricture. EoE endoscopic appearances will be analyzed by the EoE-EREFS, a scoring system for inflammatory and fibrostenotic features of the disease. Proximal and distal esophageal areas will be scored, with the score for each region ranging from 0 to 9, and the overall score ranging from 0 to 18. Higher scores indicate more extensive disease.

    Time frame: Week 24, Week 52

  2. Change from baseline in EoE-HSS (Histologic scoring system) grade score

    EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities are scored using a 4-point scale (0 normal; 3 maximum change).

    Time frame: Week 24

  3. Change from baseline in EoE-HSS (Histologic scoring system) stage score

    EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities are scored using a 4-point scale (0 normal; 3 maximum change).

    Time frame: Week 24

  4. Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels

    The peak esophageal eosinophil count is based on 2-4 esophageal biopsies from 2-3 locations.

    Time frame: Week 52

  5. Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score

    The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia.

    Time frame: Week 52

  6. Endoscopic response of total EREFS score of 0 to ≤2 with no score > 1 for any of the components and no worsening in any individual component from baseline accross all esophageal levels

    EoE endoscopic appearances will be analyzed by the EoE-EREFS, a scoring system for inflammatory and fibrostenotic features of the disease. For each of the EREFS compontents a maximum score across proximal, mid and distal esophageal areas will be selected, with the scores for edema and stricture ranging from 0 to 1, exudates and furrows ranging from 0 to 2, fixed rings ranging from 0 to 3, and overall maximum score ranging from 0 to 9.

    Time frame: Week 52

  7. Endoscopic inflammatory remission of EREFS inflammatory subscore (including edema, exudate, and furrows components) of 0 with no worsening in rings or stricture from baseline across all esophageal levels)

    EoE endoscopic appearances will be analyzed by the EoE-EREFS, a scoring system for inflammatory and fibrostenotic features of the disease. For each of the EREFS compontents a maximum score across proximal, mid and distal esophageal areas will be selected, with the scores for edema and stricture ranging from 0 to 1, exudates and furrows ranging from 0 to 2, fixed rings ranging from 0 to 3, and overall maximum score ranging from 0 to 9.

    Time frame: Week 52

  8. Total endoscopic remission of total EREFS score of 0 across all esophageal levels

    EoE endoscopic appearances will be analyzed by the EoE-EREFS, a scoring system for inflammatory and fibrostenotic features of the disease. For each of the EREFS compontents a maximum score across proximal, mid and distal esophageal areas will be selected, with the scores for edema and stricture ranging from 0 to 1, exudates and furrows ranging from 0 to 2, fixed rings ranging from 0 to 3, and overall maximum score ranging from 0 to 9.

    Time frame: Week 52

Other outcomes

  1. Change from baseline in peak esophageal eosinophil count (EOS/HPF)

    The EOS/HPF is a method of evaluating esophageal inflammation by histological response of eosinophils per high power field (HPF).

    Time frame: Week 24, Week 52

  2. Changes from baseline in PEESS Module at Week 24 (adolescents only).

    The PEESS is an 20-item assessment of EoE symptom severity and frequency validated for use in patients aged 8 to 18 years. The overall score ranges from 0 to 80, with higher scores representing more severe and frequent EoE symptoms.

    Time frame: Week 24, Week 52

  3. Change from baseline in EoE-HSS (Histologic scoring system) stage score

    EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Extent (stage) of abnormalities is scored using a 4-point scale (0 normal; 3 maximum change).

    Time frame: Week 52

  4. Change from baseline in EoE-HSS (Histologic scoring system) grade score

    EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) of abnormalities is scored using a 4-point scale (0 normal; 3 maximum change).

    Time frame: Week 52

  5. Serum tezepelumab concentration

    PK samples will be collected pre-dose. Tezepelumab concentration in serum is determined using bioanalytical method.

    Time frame: Weeks 0, 4, 12, 24, and 52

  6. Anti-drug antibody

    Anti-drug antibody is determined using bioanalytical method.

    Time frame: Weeks 0, 12, 24, and 52

07

Study locations

124 sites
  • Research Site
    Phoenix, Arizona 85016, United States
  • Research Site
    Little Rock, Arkansas 72202, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Inverness, Florida 34452, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Saint Augustine, Florida 32086, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Chesterfield, Michigan 48047, United States
  • Research Site
    Lincoln, Nebraska 68503, United States
  • Research Site
    Ocean City, New Jersey 07712, United States
  • Research Site
    Brooklyn, New York 11235, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Uniontown, Pennsylvania 15401, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    South Brisbane, QL 4101, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Bruges, 8310, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Brasília, 71681-603, Brazil
  • Research Site
    Caxias do Sul, 95070-560, Brazil
  • Research Site
    Curitiba, 80250-060, Brazil
  • Research Site
    Curitiba, 80440-220, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Hamilton, Ontario L8S 1G5, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • Research Site
    Ottawa, Ontario K1H 1E4, Canada
  • Research Site
    Windsor, Ontario N8X 2G1, Canada
  • Research Site
    Beijing, 100020, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310052, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Shanghai, 200000, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Králové, 500 12, Czechia
  • Research Site
    Prague, 190 00, Czechia
  • Research Site
    Gistrup, 9260, Denmark
  • Research Site
    Køge, 4600, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    München, 81675, Germany
  • Research Site
    Athens, 11521, Greece
  • Research Site
    Athens, 11527, GR, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Thessaloniki, 56429, Greece
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 4920235, Israel
  • Research Site
    Petah Tikva, 4941492, Israel
  • Research Site
    Tel Aviv, 62748, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Tel HaShomer, 52620, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Akita, 010-8543, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Himeji, 670-8560, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kawasaki-shi, 211-0063, Japan
  • Research Site
    Maebashi, 371-8511, Japan
  • Research Site
    Minatoku, 108-8329, Japan
  • Research Site
    Osaka, 545-8586, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Shinjuku-ku, 162-8655, Japan
  • Research Site
    Yamagata, 990-9585, Japan
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Rotterdam, 3015 GD, Netherlands

Showing the first 100 of 124 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2026, 44 months.

Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 17, 2022
StartActual
Nov 10, 2022
Primary completionActual
Jul 14, 2026
CompletionEst.
Mar 23, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 Israel, 1 New Zealand)
  • Research Site · Tel HaShomer, Israel
  • Research Site · Wellington, New Zealand
Show 2 removed
  • Research Site · Tel Litwinsky, Israel
  • Research Site · Newtown, New Zealand
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Israel, 1 New Zealand)
    • Research Site · Tel HaShomer, Israel
    • Research Site · Wellington, New Zealand
    Show 2 removed
    • Research Site · Tel Litwinsky, Israel
    • Research Site · Newtown, New Zealand
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05583227
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Nov 10, 2022
Primary completion
Jul 14, 2026
Completion
Mar 23, 2027 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion